B of A Securities Initiates Coverage On Parabilis Medicines with Buy Rating, Announces Price Target of $45

Benzinga Newsdesk www.benzinga.com Positive 56.4%

Neg 0% Neu 0% Pos 56.4%

B of A Securities analyst Tazeen Ahmad initiates coverage on Parabilis Medicines (NASDAQ:PBLS) with a Buy rating and announces Price Target of $45.